Tags : ticagrelor

PhaseBio Reports First Patients Dosing in its P-III REVERSE-IT Study

Shots: The company has reported the expansion of its P-III REVERSE-IT study for bentracimab in Canada where the first patients from major health centers globally have been enrolled (approx. 200 patients) and dosed Bentracimab demonstrated sustained reversal of the antiplatelet activity of Brilinta (ticagrelor). In a translational study, bentracimab achieved equivalent reversal of branded ticagrelor […]Read More